South African guideline for the use of chronic opioid therapy for chronic non-cancer pain

M Raff,1 BSc, MB ChB, FCA (SA); J Crosier,1 MB ChB, ChM, FRCS, FCS (SA); S Eppel,1 MB ChB, FRCS (Edin), ABU (USA); H Meyer,1 MB ChB, MPraxMed, MFGP (SA), FCFP (SA); B Sarembock,2 MB ChB, FCP (SA), RHEUM (SA); D Webb,4 BSc (Hons), MB ChB

1 Christiaan Barnard Memorial Hospital, Cape Town, South Africa
2 Department of Family Medicine, Faculty of Health Sciences, University of Pretoria, South Africa
3 Rheumatic Diseases Unit, Groote Schuur Hospital, Cape Town, South Africa
4 Pattacus Medical Consulting, Johannesburg, South Africa

Corresponding author: M Raff (raffs@iafrica.com)

This guideline is endorsed by the following professional groups: Cape Pelvic Pain Society, PainSA, South African Rheumatism and Arthritis Association, and South African Society of Anaesthesiologists.

Disclaimer. While every effort has been made to ensure the accuracy of the contents at the time of publication, the authors do not guarantee the accuracy of the information contained nor accept any liability, with respect to loss, damage, injury or expense, arising from any errors or omissions in the contents of this work. Reference in the guideline to specific pharmaceutical products does not imply endorsement of any of these products.


Quick Reference Guide

1. General management

- Chronic non-cancer pain (CNCP) is defined as pain lasting for >90 days and beyond the expected time for tissue healing.
- CNCP is often associated with psychological comorbidities (anxiety and depression) and limitation of physical function.
- Management of CNCP requires a multimodal, multidisciplinary approach to address:
  - pain and comorbidities
  - psychological issues
  - functional rehabilitation
  - social issues.
- Patients should be referred to specialist practitioners for interventions when appropriate, and thereafter referred back to the general practitioner for continued care.
- Communication between the patient's healthcare team is mandatory to establish roles and expectations for continuity of care and safe use of opioids.
- Patients should identify with one doctor (usually the general practitioner) who accepts primary responsibility for their overall medical care and who should coordinate communication and consultation among clinicians.

2. Indications for opioids

- Opioids may be appropriate in carefully selected patients with moderate to severe pain, which:
  - significantly and adversely affects quality of life, or
  - has not responded to non-pharmacological and non-opioid pharmacological therapies.
- Opioids are not appropriate as the primary medication of choice for pain disorders with strong psychosocial contributing factors.

3. Before initiating COT

- Establish a diagnosis and the cause of the pain.
- Estimate the pain intensity and functional impairment.
- Risk stratify the patient in terms of potential benefits and harms of opioid therapy to assess their suitability for COT.

3.1 Patient assessment and diagnosis

- Patient's pain disorder
- Pain intensity
- Functional impairment (impact of pain on work, school/studying, home and leisure activities)
- General medical condition
- Sleeping pattern
- Psychosocial history (living arrangements, family/social support, family obligations, work status)
- Psychiatric status
- Substance use history
- Other medications

Assessment tools to evaluate patients for COT (Appendix 1 and 2)

<table>
<thead>
<tr>
<th>Tool</th>
<th>Purpose</th>
<th>When to complete</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPI</td>
<td>To evaluate physical and psychosocial components of pain</td>
<td>All visits</td>
</tr>
<tr>
<td>ORT</td>
<td>To evaluate risk of opioid abuse</td>
<td>Initial visit</td>
</tr>
</tbody>
</table>

COT = chronic opioid therapy; BPI = Brief Pain Inventory; ORT = Opioid Risk Tool.

The full version of this guideline is available online. Use the QR code to access.
3.2 Explain treatment options and address expectations

- Total pain relief is rarely achieved.
- Goals of therapy are pain reduction and functional improvement:
  - Clinically meaningful improvement is at least 30% reduction in pain (or ≥2 points on a 0 - 10 numerical rating scale) and/or 30% improvement in function.
- Caution patients against unrealistic expectations.
- Potential benefits, adverse effects, complications and risks of COT.
- Alternatives to COT.
- Consider asking the patient to sign an opioid agreement (Appendix 3).
- Initial course of COT is viewed as a short-term trial, which will be continued if response is satisfactory.
- Positive clinical response to COT may take a few days to become apparent.

Detailed notes of all assessments, discussions and treatment decisions should be maintained at all visits.

4. Choice of opioid

- Opioid analgesics for CNCP may be administered orally or transdermally.
- When choosing an appropriate opioid, consider health status, pain severity, previous exposure to opioids, attainment of therapeutic goals and predicted or observed harms, concomitant medications.
- Use immediate release (IR) oral opioids to initiate therapy and titrate to an effective dose.
- Once pain control is stable, if possible, switch to long-acting (controlled release (CR); extended release (ER), sustained release (SR)) oral opioid or transdermal opioid patch.

5. Initiation and titration of COT

- Start with a low dose: ≤10 mg/day oral morphine equivalents.
- Reassess dose after 72 h (clinical improvement and tolerability).
- Dose may be slowly increased by not more than 10 mg morphine equivalents per day over 4 - 6 weeks.
- Maximum daily dose should preferably not exceed 90 mg oral morphine equivalents.
- If repeated dose escalations are required, consider:
  - increase in the intensity of the underlying pain condition (disease progression)
  - development of an additional painful condition
  - opioid tolerance
  - opioid-induced hyperalgesia
  - drug abuse (e.g. recreational use).

Step-wise approach to opioid selection

<table>
<thead>
<tr>
<th>First-line</th>
<th>Severe pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine or tramadol</td>
<td>Morphine, high-dose oxycodone, hydromorphone, or buprenorphine</td>
</tr>
<tr>
<td>Morphone, low-dose oxycodone, dihydrocodeine, hydromorphone or buprenorphine</td>
<td>Fentanyl</td>
</tr>
</tbody>
</table>

Oral opioids: Suggested initial dose and titration*†‡

<table>
<thead>
<tr>
<th>Opioid</th>
<th>Initial dose</th>
<th>Min. time interval for increase (days)</th>
<th>Suggested dose increase</th>
<th>Min. daily dose before converting IR to CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine (alone/in combination with paracetamol/ASA)</td>
<td>15 - 30 mg 4-hourly as required</td>
<td>7</td>
<td>15 - 30 mg/day, max. 600 mg/day†</td>
<td>100 mg</td>
</tr>
<tr>
<td>Tramadol (37.5 mg) + paracetamol (325 mg)</td>
<td>1 tablet 4 - 6-hourly</td>
<td>7</td>
<td>1 - 2 tablets 4 - 6-hourly as needed, max. 8 tablets/day</td>
<td>3 tablets</td>
</tr>
<tr>
<td>Tramadol</td>
<td>50 mg 4 - 6-hourly</td>
<td>Max. dose: 400 mg/day</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>SR tramadol</td>
<td>100 mg 12-hourly</td>
<td>Max. dose: 400 mg/day</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>IR morphine</td>
<td>5 - 10 mg 4-hourly as needed, max. 40 mg/day</td>
<td>7</td>
<td>5 - 10 mg/day</td>
<td>20 - 30 mg</td>
</tr>
<tr>
<td>CR morphine</td>
<td>10 - 30 mg 12-hourly</td>
<td>Min. 2, recommended: 14</td>
<td>5 - 10 mg/day</td>
<td>NA</td>
</tr>
<tr>
<td>IR oxycodone</td>
<td>5 - 10 mg 6-hourly as needed, max. 40 mg/day</td>
<td>7</td>
<td>5 mg/day</td>
<td>20 mg</td>
</tr>
<tr>
<td>CR oxycodone</td>
<td>10 - 20 mg 12-hourly, max. 40 mg/day</td>
<td>Min. 2, recommended: 14</td>
<td>10 mg/day</td>
<td>NA</td>
</tr>
<tr>
<td>ER hydromorphone</td>
<td>4 mg daily, max. 16 mg/day</td>
<td>Min. 2, recommended: 14</td>
<td>2 - 4 mg/day</td>
<td>NA</td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td>30 mg 6-hourly</td>
<td>Min. 2, recommended: 7</td>
<td>Increase to 30 mg every 4 h, max. 240 mg/day</td>
<td>NA</td>
</tr>
</tbody>
</table>

*IR = immediate release; CR = controlled release; ASA = acetylsalicylic acid; ER = extended release; SR = sustained release.
†Modified from the Canadian National Opioid Use Guideline Group (2010).15
‡Due to a genetic polymorphism that influences the response to opioid analgesics, there is inter-individual variation in the doses required for adequate analgesia. Some patients will require considerably higher opioid doses than others.
§Paracetamol dose should not exceed 3 g/day.
6. Consider switching to another opioid if:

- Analgesia is inadequate despite dose escalation
- Adverse effects are intolerable
- Stable pain control is achieved on IR opioid and it is appropriate to switch to a long-acting formulation or transdermal opioid patch.

7. Breakthrough pain

- Consider as-needed IR opioid for rescue analgesia.
- If continuous rescue doses are required, up-titrate maintenance analgesic dose by adding the extra dose per day required for breakthrough pain.

8. Long-term opioid prescribing

When a trial of opioid has been successful, treatment may be continued until:

- the underlying painful condition resolves
- the patient receives a definitive pain relieving intervention (e.g. joint replacement)
- the patient no longer derives benefit from opioid treatment
- the patient develops intolerable side-effects; or
- there is evidence of addiction, tolerance, dependence or opioid-induced hyperalgesia. It should be noted that patients who are suffering with severe pain rarely become addicted to opioids. They may require increasing doses of opioids as a result of opioid tolerance and this must be differentiated from addiction.

9. Discontinuing opioids

- Reduce dose slowly by approximately 10% per day or per week.
- Dose should be tapered more slowly in patients who are anxious about discontinuing COT and in those who are suspected of being physically dependent on opioids.
- When one-third of the original dose is reached, reduce the rate of tapering to one-half or less of the initial rate.
- If the patient experiences withdrawal symptoms or an increase in pain during tapering, discontinue dose reduction and consider increasing the current dose.

---

### Equianalgesic doses for conversion from one oral opioid to another*

<table>
<thead>
<tr>
<th>Opioid</th>
<th>Equivalence to 30 mg morphine (mg)</th>
<th>Conversion to/from oral morphine equivalent – multiply by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>30</td>
<td>1</td>
</tr>
<tr>
<td>Codeine</td>
<td>200</td>
<td>0.15</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>20</td>
<td>1.5</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td>180</td>
<td>0.16</td>
</tr>
<tr>
<td>Tramadol</td>
<td>–1:10†</td>
<td>6</td>
</tr>
</tbody>
</table>

*Adapted from the Canadian National Opioid Use Guideline Group (2010).

† If converting from opioids other than morphine, calculate the equipotent morphine dose for the current analgesic and use this dose to convert to the new opioid. The new opioid should be initiated at 50% of the calculated equianalgesic dose.

‡ Morphine dose equivalence not established, but approximates to 1:10 of morphine to tramadol.

### Approximate equipotent doses for conversion from oral morphine to transdermal opioids

<table>
<thead>
<tr>
<th>Oral morphine to transdermal fentanyl†‡</th>
<th>Conversion rate 150:1, e.g. 120 mg morphine over 24 h: 120 ÷ 150 = 0.8 mg fentanyl; 0.8 × 1 000 = 800 μg fentanyl over 24 h = 33.3 μg/h. Round up or down to appropriate patch.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral morphine equivalent (mg/24 h)</td>
<td>60 - 134</td>
</tr>
<tr>
<td>Transdermal fentanyl (μg/h)</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>62</td>
</tr>
<tr>
<td></td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>100</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral morphine to transdermal buprenorphine§¶</th>
<th>Conversion rate is 75 - 100:1. The conversion rate used here is based on 75:1, e.g. 30 mg morphine over 24 h: 30 ÷ 75 = 0.4 mg buprenorphine; 0.4 × 1 000 = 400 μg buprenorphine over 24 h = 16.6 μg/h. Round up or down to appropriate patch.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral morphine equivalent (mg/24 h)</td>
<td>10</td>
</tr>
<tr>
<td>Transdermal buprenorphine (μg/h)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>52.5</td>
</tr>
<tr>
<td></td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>140</td>
</tr>
</tbody>
</table>

*Adapted from the Canadian National Opioid Use Guideline Group (2010).

† Conversion rate is 150:1, e.g. 120 mg morphine over 24 h: 120 ÷ 150 = 0.8 mg fentanyl; 0.8 × 1 000 = 800 μg fentanyl over 24 h = 33.3 μg/h. Round up or down to appropriate patch.

‡ Formulations include 12, 25, 50, 75 and 100 μg/h patches, but the 12 μg/h patch is generally used for dose adjustment rather than initiation of fentanyl treatment.

§ Adapted from the British Pain Society (2010).

¶ Conversion rate is 75 - 100:1. The conversion rate used here is based on 75:1, e.g. 30 mg morphine over 24 h: 30 ÷ 75 = 0.4 mg buprenorphine; 0.4 × 1 000 = 400 μg buprenorphine over 24 h = 16.6 μg/h. Round up or down to appropriate patch.

### Common opioid-related adverse effects and their management

<table>
<thead>
<tr>
<th>Adverse effect</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea/vomiting</td>
<td>Anti-emetic therapies (oral or suppository); it is advisable to concurrently prescribe a prophylactic anti-emetic for a few days when initiating opioid therapy</td>
</tr>
<tr>
<td>Constipation</td>
<td>Increase fluid and fibre intake; stool softeners; laxatives</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Antihistamine</td>
</tr>
<tr>
<td>Sedation, clouded mentation</td>
<td>Pharmacological therapies are not recommended</td>
</tr>
</tbody>
</table>

---
10. Opioid-related adverse effects

Adverse effects are usually manageable and most pronounced when initiating or increasing the dose.

10.1 For intolerable adverse effects, consider

- Reducing the opioid dose.
- Switching to another opioid formulation or route of administration.
- Discontinuing the opioid and instituting alternative pain management strategies.

11. Driving and working while on opioids

Patients should be advised to avoid driving, working under hazardous conditions or working with hazardous machinery if:

- the condition for which they are being treated has physical consequences that might impair their driving ability, concentration or coordination
- they feel unfit to drive or work
- they have constant severe pain
- they have not been sleeping
- they have just started opioid treatment
- their dose of opioids has been recently adjusted upwards or downwards (as withdrawal may have an impact on capability)
- they have consumed alcohol or other drugs that can produce an additive sedative effect.

12. When to refer to a pain clinician or multidisciplinary pain unit

- Unable to make a definite diagnosis of the cause of pain
- Significant comorbidities or other factors that may complicate opioid use (e.g. psychiatric comorbidities, severe renal impairment, etc.)
- Inadequate response to opioid analgesia, despite titration to 90 mg/day oral morphine equivalent
- Unmanageable opioid-related side-effects
- Indications of inappropriate drug use.

---

**Clinical features of opioid toxicity and withdrawal**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Toxicity</strong></td>
<td>Pinpoint pupils</td>
</tr>
<tr>
<td></td>
<td>Sedation (falling asleep during conversation or activity)</td>
</tr>
<tr>
<td></td>
<td>Slow respiration</td>
</tr>
<tr>
<td></td>
<td>Visible cyanosis, e.g. lips, ears, nose (in severe cases)</td>
</tr>
<tr>
<td></td>
<td>Myoclonic jerks</td>
</tr>
<tr>
<td></td>
<td>Snoring when asleep</td>
</tr>
<tr>
<td></td>
<td>Agitation</td>
</tr>
<tr>
<td></td>
<td>Confusion</td>
</tr>
<tr>
<td></td>
<td>Vivid dreams, nightmares or hallucinations</td>
</tr>
<tr>
<td><strong>In more severe cases</strong></td>
<td>Hypotension</td>
</tr>
<tr>
<td></td>
<td>Coma</td>
</tr>
<tr>
<td></td>
<td>Convulsions</td>
</tr>
<tr>
<td><strong>Withdrawal</strong></td>
<td>Sweating</td>
</tr>
<tr>
<td></td>
<td>Mydriasis</td>
</tr>
<tr>
<td></td>
<td>Pilo-erection</td>
</tr>
<tr>
<td></td>
<td>Yawning</td>
</tr>
<tr>
<td></td>
<td>Abdominal cramps/vomiting/diarrhoea</td>
</tr>
<tr>
<td></td>
<td>Bone and muscle pain</td>
</tr>
<tr>
<td></td>
<td>Increase in usual pain</td>
</tr>
<tr>
<td></td>
<td>Restlessness</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
</tr>
<tr>
<td></td>
<td>Rhinorrhoea</td>
</tr>
<tr>
<td></td>
<td>Lacrimation</td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
</tr>
<tr>
<td><strong>In more severe cases</strong></td>
<td>Hypotension</td>
</tr>
<tr>
<td></td>
<td>Coma</td>
</tr>
<tr>
<td></td>
<td>Convulsions</td>
</tr>
</tbody>
</table>

---

**10. Opioid-related adverse effects**

10.1 For intolerable adverse effects, consider

- Reducing the opioid dose.
- Switching to another opioid formulation or route of administration.
- Discontinuing the opioid and instituting alternative pain management strategies.

**11. Driving and working while on opioids**

Patients should be advised to avoid driving, working under hazardous conditions or working with hazardous machinery if:

- the condition for which they are being treated has physical consequences that might impair their driving ability, concentration or coordination
- they feel unfit to drive or work
- they have constant severe pain
- they have not been sleeping
- they have just started opioid treatment
- their dose of opioids has been recently adjusted upwards or downwards (as withdrawal may have an impact on capability)
- they have consumed alcohol or other drugs that can produce an additive sedative effect.

**12. When to refer to a pain clinician or multidisciplinary pain unit**

- Unable to make a definite diagnosis of the cause of pain
- Significant comorbidities or other factors that may complicate opioid use (e.g. psychiatric comorbidities, severe renal impairment, etc.)
- Inadequate response to opioid analgesia, despite titration to 90 mg/day oral morphine equivalent
- Unmanageable opioid-related side-effects
- Indications of inappropriate drug use.
Patients with chronic non-cancer pain

Initial steps
- Comprehensive assessment
- Assessment of risk of misuse
- Screening tests: BPI, ORT

Diagnosis
- X-rays, MRI, CT, neurophysiological studies
- Psychological evaluation (basic)
- Precision diagnostic interventions (optional)
- Consultation/s as needed

Medical necessity
- Physical diagnosis
- Non-opioid therapy
- Physical modalities
- Behavioural interventions (optional)
- Interventional pain management (optional)
- Other alternatives
- Consultation/s as needed

Assess effectiveness of opioid therapy

Informed decision-making
- Opioid agreement
- Random evaluations including pill counts and urine drug testing

Initial treatment (8 - 12 weeks)
- Stratification of risk
- Understanding opioids
- Initiation with low-dose, short-acting opioid therapy
- Titrate

Adherence monitoring
- Prescription drug monitoring programmes
- Urine drug testing
- Pill counts
- Behavioural assessment during each visit

Side-effects
- Driving and working
- Sedation
- Constipation
- Breathing difficulties

Discontinue
- Persistent or new pain
- Abuse, misuse
- Lack of analgesia
- Lack of activity
- Adverse effects
- Aberrant behaviour
- Taper and discontinue
- Repeat comprehensive evaluation
- Consider consultation

Continue
- Analgesia of 30% and/or activity increase by 30%
- No misuse, abuse, adverse effects, manageable
- Continue monitoring
- Wean, discharge, or maintain

Treatment goals
- Decrease pain by 30% and/or increase function by 30%
- Minimal adverse effects

Algorithm for the initiation and use of COT. Adapted with permission from Manchikanti et al. [5] (COT = chronic opioid therapy; BPI = Brief Pain Inventory; ORT = Opioid Risk Tool; MRI = magnetic resonance imaging; CT = computed tomography.)
Appendix 1. Brief Pain Inventory*

Name: _______________________________________
Date: _______________________________________
Time: _______________________________________

1. Throughout our lives, most of us have had pain from time to time (such as minor headaches, sprains and toothaches). Have you had pain other than these everyday kinds of pain today?
☐ YES  ☐ NO

2. On the diagram, shade the area where you feel pain. Put an X on the area that hurts the most.

3. Please rate your pain by circling the number that best describes your pain at its worst in the past 24 h.

   No pain   Pain as bad as you can imagine

   0  1  2  3  4  5  6  7  8  9  10

4. Please rate your pain by circling the number that best describes your pain at its least in the past 24 h.

   No pain   Pain as bad as you can imagine

   0  1  2  3  4  5  6  7  8  9  10

5. Please rate your pain by circling the number that best describes your pain on average.

   No pain   Pain as bad as you can imagine

   0  1  2  3  4  5  6  7  8  9  10

6. Please rate your pain by circling the number that tells how much pain you have right now.

   No pain   Pain as bad as you can imagine

   0  1  2  3  4  5  6  7  8  9  10

7. What treatments or medications are you receiving for your pain?

8. In the past 24 h, how much relief have pain treatments or medications provided? Please circle the percentage that shows how much relief you have received.

   0%  10%  20%  30%  40%  50%  60%  70%  80%  90%  100%

   No relief  Complete relief

9. Circle the number that describes how, during the past 24 h, pain has interfered with your:

   A. General activity

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

   B. Mood

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

   C. Walking ability

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

   D. Normal work (includes both work outside the home and housework)

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

   E. Relations with other people

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

   F. Sleep

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

   G. Enjoyment of Life

   Does not interfere  Completely interferes

   0  1  2  3  4  5  6  7  8  9  10

Appendix 2. Opioid Risk Tool*

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Male, score (max. score)</th>
<th>Female, score (max. score)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history (parents and siblings)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol abuse</td>
<td>(3)</td>
<td>(1)</td>
</tr>
<tr>
<td>Illegal drug use</td>
<td>(3)</td>
<td>(2)</td>
</tr>
<tr>
<td>Prescription drug abuse</td>
<td>(4)</td>
<td>(4)</td>
</tr>
<tr>
<td>Personal history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol abuse</td>
<td>(3)</td>
<td>(3)</td>
</tr>
<tr>
<td>Illegal drug use</td>
<td>(4)</td>
<td>(4)</td>
</tr>
<tr>
<td>Prescription drug abuse</td>
<td>(5)</td>
<td>(5)</td>
</tr>
<tr>
<td>Mental health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis of ADD, OCD, bipolar disorder or schizophrenia</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>Diagnosis of depression</td>
<td>(1)</td>
<td>(1)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 16 - 45 years</td>
<td>(1)</td>
<td>(1)</td>
</tr>
<tr>
<td>History of pre-adolescent sexual abuse</td>
<td>(0)</td>
<td>(3)</td>
</tr>
</tbody>
</table>

Total score

Total score risk category:
- 0 - 3 = low risk: 6% chance of developing problematic behaviours
- 4 - 7 = moderate risk: 28% chance of developing problematic behaviours
- ≥8 = high risk: >90% chance of developing problematic behaviours

ADD = attention deficit disorder; OCD = obsessive-compulsive disorder.
*Reproduced with permission from Webster LR and Webster RM.13

Appendix 3. Sample opioid agreement

I (patient's name) understand that Dr is prescribing opioid medication for me to treat my chronic pain. The opioid medication that has been prescribed is: .

The risks and benefits of this medicine have been explained to me and I understand the following:
- the medicine may have certain side-effects including, but not limited to, drowsiness, dizziness, loss of coordination, constipation, nausea, vomiting and itching
- the medication may impair my ability to drive a motor vehicle, operate hazardous machinery or work under hazardous conditions
- alcohol and certain other medications may increase the risk of side-effects while I am taking opioid medication, or may reduce the effectiveness of my pain medication
- although the risk is low, addiction to opioid medication can occur; addiction is more likely to occur in people with a personal or family history of drug or alcohol abuse and/or addiction
- physical dependence to opioid medication may occur and may result in withdrawal symptoms if the medication is stopped abruptly
- opioid medication may not provide complete pain relief; if the pain or ability to be active does not improve after a reasonable trial of opioid medication, the medication may be stopped.

I agree to the following:
1. Only Dr will prescribe opioids for me, and I will not seek or accept opioid medications from anyone else.
2. I will take my opioid medication exactly as instructed by Dr and will not take it in larger doses or more frequently than instructed.
3. I will tell Dr about all other medications I am taking and about any personal/family history of alcohol/drug abuse or illegal drug activity. I will not use any other prescribed or over-the-counter medication without discussing it with him/her first.
4. I will not give my opioid medication to anyone else and I will store it in a safe and secure place and out of the reach of children.
5. (Females only) I will tell my doctor immediately if I am planning to become pregnant or if I think that I am or might be pregnant.
6. My medical practitioner may decide to discontinue my opioid medication if my pain or ability to be active does not improve, or if I do not comply with any of the above.

Patient signature: __________________________ Date: __________________________ Witness: __________________________